Bonum Therapeutics, Inc.

Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

[Bonum Therapeutics, Inc. @BonumTx]

We're saying goodbye to X and saying hello to bluer skies! Follow us on Bluesky at @bonumtx.com and on LinkedIn to stay connected and hear about our latest updates.

[Bonum Therapeutics, Inc. @BonumTx]

The Bonum team had a fantastic time sharing some of our work and connecting with old friends and new at #SITC24. Thanks to everyone @sitcancer for putting on such a great meeting. Looking forward to next year!

[Bonum Therapeutics, Inc. @BonumTx]

With growth comes change & the need for more space! Bonum has moved to 1150 Eastlake. Thanks to AAHI for housing us during our formative years & to our BOD—shown with CEO John Mulligan—for their guidance during this exciting transition. More at @PSBJ: https://t.co/8NAHj0gwcU

[Bonum Therapeutics, Inc. @BonumTx]

Happy second anniversary, Bonum! No 'terrible twos' here. Having cut our teeth as Good Therapeutics, we're up and running with our lead candidate, cLAG3-IL2, now in preclinical development. Thank you Team Bonum, and cheers to many more years of great discovery! 🥂

[Bonum Therapeutics, Inc. @BonumTx]

👀 in the #PNW: CSO Diane Hollenbaugh repping the oncology research community & the collective good they do! As National Cancer Research Month ends, Bonum recognizes the tireless efforts & enduring optimism of those working to create a better future. #NCRM2024 #ScienceSelfie

[Bonum Therapeutics, Inc. @BonumTx]

Heading to the Keystone Symposia’s “Antibodies as Drugs: The Art in Antibody Engineering” conference, May 5-8? Don’t miss your chance to learn about Bonum’s technology to generate conditionally activated protein therapeutics, & our lead asset, cLAG3-IL2: https://t.co/0uDP0QjxMM

[Bonum Therapeutics, Inc. @BonumTx]

Inspiring science? Check ✅ Fueling progress? Check ✅ Revolutionizing care? Check ✅

Bonum enjoyed sharing data on our lead candidate & and learning about the latest advances in cancer science & medicine at #AACR24!

Next Up: #KSAntibodyEng24 in Breckenridge, CO, May 5-8, 2024

[Bonum Therapeutics, Inc. @BonumTx]

We were delighted to present our poster at #AACR24 this morning! Missed us? Take a closer look at the preclinical data on our lead program, cLAG3-IL2, demonstrating the power of Bonum's technology platform: https://t.co/RrfFuzghEX

[Bonum Therapeutics, Inc. @BonumTx]

Heading to #AACR24? Bonum will be sharing preclinical data for the first time on our lead program, cLAG3-IL2, demonstrating the power of our technology platform. Don't miss our poster on April 9th! For more info ⬇️
https://t.co/wuQRfz81yd

[Bonum Therapeutics, Inc. @BonumTx]

Bonum is focused on a proven technology that utilizes regulation to create targeted, highly active & less toxic medicines. Connect with John Mulligan, Diane Hollenbaugh, Justin Killebrew & Shannon Okada at #AACR24 as they share preclinical data on cLAG3-IL2.

[Bonum Therapeutics, Inc. @BonumTx]

Meeting investors', buyers', and sellers' goals isn't easy. Bonum's CBO Neela Patel offers advice on how to negotiate a winning deal that leaves all parties positioned for success in the Spring 2024 Issue of @DDWJournal, starting on page 62: https://t.co/9zqXTuncGV

[Bonum Therapeutics, Inc. @BonumTx]

Heading to #AACR24? Don't miss Bonum's presentation of pre-clinical data on our lead program, cLAG3-IL2. For more on our powerful technology platform, check out The Bio Report podcast w/ Bonum's Diane Hollenbaugh & Neela Patel. Listen now: https://t.co/uNIdylyO6F

@dslevine

[Bonum Therapeutics, Inc. @BonumTx]

TODAY: Don't miss Bonum's CBO Neela Patel at the Fierce BD&L Summit for Life Sciences 2024 as part of the “Creative Deal Structures for Traditional Asset Based Deals" panel discussion from 1:15-2:00pm PDT. For more info: https://t.co/7iltgclJfM

#FierceBiotech #FiercePharma

[Bonum Therapeutics, Inc. @BonumTx]

Bonum's CBO Neela Patel will be at Fierce BD&L Summit for Life Sciences 2024 as part of the “Creative Deal Structures for Traditional Asset Based Deals" panel at 1:15pm PDT on Monday, March 11. More info & registration: https://t.co/J7JQynjWh1

#FierceBiotech #FiercePharma

[Bonum Therapeutics, Inc. @BonumTx]

Bonum will be sharing preclinical data for the first time at #AACR24 on our lead program, cLAG3-IL2, demonstrating the power of our technology platform. Don't miss our poster on April 9th! For more info ⬇️
https://t.co/wuQRfz81yd

[Bonum Therapeutics, Inc. @BonumTx]

At Bonum, we believe that treatment should be accessible to all & every patient deserves a chance for hope. On #WorldCancerDay, we applaud those who work to #CloseTheCareGap. Learn more about the campaign to create more equitable access to cancer services. https://t.co/p4VH2T75BF

[Bonum Therapeutics, Inc. @BonumTx]

We're honored to be included in BioSpace's 'NextGen Class of 2024.' Bonum is excited to head into this new year with a talented team & a robust portfolio of pre-clinical assets based on a validated platform. https://t.co/BSq2lDI3Gn

[Bonum Therapeutics, Inc. @BonumTx]

Bonum Therapeutics would like to thank all who contributed to our successes in 2023. We look forward to exciting things to come in 2024!

[Bonum Therapeutics, Inc. @BonumTx]

Founder & CEO @JohnMulligan42 & Chief Business Officer Neela Patel had a fantastic time discussing all things Bonum with @mattpillar on this week's #BusinessOfBiotech podcast. Thanks for a great conversation, Matt! https://t.co/6cAziENzKy

[Bonum Therapeutics, Inc. @BonumTx]

Can biotechs thrive when the market’s against them? “Yes,” says Founder & CEO, @JohnMulligan42, who shares tips on doing important science and running a successful biotech business in less-than-ideal market conditions w/ @PharmaVoice's Michael Gibney. https://t.co/hLfK2ULxbF